Grand Hopital De L Est Francilien

The intensive care unit at Grand Hopital De L Est Francilien is conducting research on a range of infectious challenges, from acute vaginal infection to drug‑resistant tuberculosis. Studies aim to evaluate new antimicrobial strategies and improve early treatment outcomes for critically ill patients.

• Live biotherapeutic product for bacterial vaginosis, vulvovaginal candidiasis, or mixed infections
• Early bactericidal activity assessment of tedizolid against Mycobacterium tuberculosis
• Comparative efficacy of novel dosing regimens versus placebo in treating vaginal infections
• Investigation of antimicrobial effectiveness in ICU‑admitted septic patients

With six investigators overseeing six trials, the site blends critical care expertise with cutting‑edge microbiology to advance therapeutic options for severe bacterial and fungal diseases.

Research in the cardiovascular domain focuses on preventing heart dysfunction and reducing event risk in patients with hypertension, frequent premature beats, and metabolic comorbidities such as type 2 diabetes. The trials test both pharmacologic and procedural approaches to protect cardiac function over the long term.

• Prophylactic treatment of asymptomatic frequent premature ventricular complexes to preserve left‑ventricular performance
• Combination therapy with vicadrostat and empagliflozin to lower cardiovascular death, heart‑failure hospitalization, or urgent visits
• Evaluation of blood‑pressure control strategies in hypertensive patients
• Long‑term cardiac outcome monitoring in patients with established cardiovascular disease

The unit’s multidisciplinary team integrates intensive‑care monitoring with cardiology expertise, offering a comprehensive platform for innovative cardiovascular research.

The oncology program at the site targets advanced malignancies of the upper gastrointestinal tract, including gastro‑oesophageal junction adenocarcinoma and stomach cancer. Trials are designed to assess novel immunotherapy combinations and their impact on disease progression.

• Comparison of FOLFIRI alone versus FOLFIRI plus Domvanalimab and Zimberelimab in advanced gastric or gastro‑oesophageal adenocarcinoma
• Evaluation of progression‑free survival with added anti‑PD1 and anti‑TIGIT agents
• Assessment of treatment response after peri‑operative platinum‑based chemotherapy
• Biomarker analysis to predict therapeutic benefit in gastrointestinal cancers

Leveraging a dedicated cancer care team, the hospital explores cutting‑edge immuno‑oncology strategies to improve outcomes for patients with difficult‑to‑treat digestive system cancers.

In the women’s health arena, investigators are evaluating new options for managing infections of the lower genital tract. The primary goal is to determine whether a novel vaginal tablet can safely and effectively treat conditions such as bacterial vaginosis and vulvovaginal candidiasis.

• Randomized, double‑blind trial of a live biotherapeutic product for acute vaginal infections
• Safety and dose‑response assessment in women with confirmed bacterial vaginosis or candidiasis
• Comparison of treatment outcomes versus placebo across multiple infection subtypes
• Evaluation of patient‑reported symptom relief and quality of life improvements

The department’s focus on female urogenital health aligns with its broader mission to provide evidence‑based therapies that enhance women's reproductive wellbeing.